Intact Vascular’s Tack Optimized Balloon Angioplasty III (TOBA III) Clinical Trial Commences Enrollment with First European Implant of the Tack Endovascular System™

The TOBA III clinical trial studies the combination of Intact Vascular’s Tack Endovascular System and the Medtronic IN.PACT® Admiral® Drug-Coated Balloon in the treatment of Peripheral Artery Disease (PAD)

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized Balloon Angioplasty III (TOBA III) clinical trial has commenced enrollment, with the first patient treated by Prof. Klaus Brechtel at the Franziskus-Hospital in Berlin, Germany.

The TOBA III study is a prospective, multi-center, single-arm study designed to investigate the safety and efficacy of the Tack Endovascular System in combination with the Medtronic Admiral drug-coated angioplasty balloon in the treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries. The Tack Endovascular System is a new technology designed to repair dissections (or tears) in the artery wall that frequently occur as a complication of balloon angioplasty. The system allows physicians to repair these dissections while leaving a minimal amount of foreign material in the artery, reducing mechanical stress on the artery, and preserving future treatment options.

Click here to read the full press details.


©2016 PACT All Rights Reserved